- Home
- MCRI vs WGS Comparison
MCRI vs WGS Comparison
Compare MCRI & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRI
- WGS
- Stock Information
- Founded
- MCRI 1972
- WGS 2017
- Country
- MCRI United States
- WGS United States
- Employees
- MCRI N/A
- WGS N/A
- Industry
- MCRI Hotels/Resorts
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- MCRI Consumer Discretionary
- WGS Technology
- Exchange
- MCRI Nasdaq
- WGS Nasdaq
- Market Cap
- MCRI 1.6B
- WGS 1.5B
- IPO Year
- MCRI 1993
- WGS N/A
- Fundamental
- Price
- MCRI $83.18
- WGS $68.43
- Analyst Decision
- MCRI Hold
- WGS Strong Buy
- Analyst Count
- MCRI 3
- WGS 5
- Target Price
- MCRI $78.33
- WGS $67.00
- AVG Volume (30 Days)
- MCRI 84.9K
- WGS 753.8K
- Earning Date
- MCRI 10-23-2024
- WGS 10-29-2024
- Dividend Yield
- MCRI 1.44%
- WGS N/A
- EPS Growth
- MCRI 2.59
- WGS N/A
- EPS
- MCRI 4.52
- WGS N/A
- Revenue
- MCRI $515,859,000.00
- WGS $267,228,000.00
- Revenue This Year
- MCRI $5.05
- WGS $43.70
- Revenue Next Year
- MCRI $1.62
- WGS $16.78
- P/E Ratio
- MCRI $18.39
- WGS N/A
- Revenue Growth
- MCRI 4.46
- WGS 29.41
- 52 Week Low
- MCRI $62.03
- WGS $1.29
- 52 Week High
- MCRI $84.43
- WGS $89.11
- Technical
- Relative Strength Index (RSI)
- MCRI 68.26
- WGS 51.05
- Support Level
- MCRI $82.65
- WGS $71.45
- Resistance Level
- MCRI $84.43
- WGS $82.18
- Average True Range (ATR)
- MCRI 1.38
- WGS 7.58
- MACD
- MCRI 0.33
- WGS -1.36
- Stochastic Oscillator
- MCRI 81.23
- WGS 17.21
About MCRI Monarch Casino & Resort Inc.
Monarch Casino & Resort Inc is engaged in providing the latest gaming, dining, and hospitality amenities. It owns and operates the Atlantis Casino Resort Spa, a hotel/casino facility in Reno, Nevada, and the Monarch Black Hawk Casino in Black Hawk. The company generates the majority of its revenue from Casinos, followed by Food & Beverage and Hotel Operations.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets. It has two segments GeneDx, which derives maximum revenue and Legacy Sema4 diagnostics.